US8664231 — Concentrated methotrexate solutions
Method of Use · Assigned to Medac Gesellschaft fuer Klinische Spezialpraeparate mbH · Expires 2029-06-01 · 3y remaining
What this patent protects
This patent protects concentrated methotrexate solutions for parenteral administration in treating inflammatory autoimmune diseases.
USPTO Abstract
Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
U-1442 |
— | chembl-chembl34259 |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.